Výsledky vyhledávání

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

Autor: Ritchlin, C., Rahman, P., Kavanaugh, A., McInnes, I.B., Puig, L., Li, S., Wang, Y., Shen, Y.-K., Doyle, M. K., Mendelsohn, A. M., Gottlieb, A. B., Perate, M., Whitman, M., Dooley, L. T., Alten, R., Birbara, C., Boh, E., Braun, J., Budd, J., Chattapadhyay, C., Chudzik, D., Claudepierre, P., Cooper, R., Drescher, E., Dutz, J., Edwards, C., Elewski, B., El-Kadi, H., Erlacher, L., Flipo, R., Fretzin, S., George, E., Gladstein, G., Griffin, R., Grisanti, M., Guenther, L., Gulliver, W., Hobbs, K., Huang, E., Ilivanova, E., Jeka, S., Khraishi, M., Kokhan, M., Korman, N., Kunynetz, R., Leonardi, C., Lessard, C., Lindquist, U., Martin, A., Matheson, R., Murphy, F., Nasonov, E., Palmer, W., Papp, K., Rech, J., Rell-Bakalarska, M., Rich, P., Rosen, C., Rudin, A., Ruppert-Roth, A., Scheinecker, C., Seigel, S., Shaikh, S., Sheeran, T., Shergy, W., Siegel, E., Sierakowski, S., Sofen, H., Szanto, S., Tahir, H., Telegdy, E., Toth, D., Walker, D., Wilson, A., Witt, M., Wollenhaupt, J., Zoschke, D., Zubrzycka, A.

Objective: Assess ustekinumab efficacy (week 24/week 52) and safety (week 16/week 24/week 60) in patients with active psoriatic arthritis (PsA) despite treatment with conventional and/or biological anti-tumour necrosis factor (TNF) agents.\ud \ud Met

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::eb7f68d6eb4312c76a04bd46737b5446
https://eprints.gla.ac.uk/104757/1/104757.pdf

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání